Your Health, We Care
The planned interim efficacy and safety analysis was performed after 149 TTP events had occurred. There was a statistically significant advantage for Sunitinib over placebo in TTP, meeting the primary endpoint. Efficacy results are summarized in Table 10 and the Kaplan-Meier curve for TTP is shown in Figure 1.
from FDA，2021.08
